2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 28th, 2025
Version: 1
Oregon Health & Science University
cancer biology
biorxiv

Long Noncoding RNAs Enforce Pancreatic Cancer Identity and Block Reprogramming

Grygoryev, D.Open in Google Scholar•Lee, S.-W.Open in Google Scholar•Frankston, C. M.Open in Google Scholar•Rakshe, S.Open in Google Scholar•Berry, M.Open in Google Scholar•Hirano, A.Open in Google Scholar•Ekstrom, T.Open in Google Scholar•Manalo, E.Open in Google Scholar•Tessier, J.Open in Google Scholar•Chow-Castro, M.Open in Google Scholaret al.

Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest malignancies, exemplifies a paradox of transcriptional plasticity and rigidity: it displays dynamic transcriptional states yet retains a stable classical epithelial identity, which resists therapeutic intervention. This rigidity reflects robust transcriptional memory, but the underlying mechanisms remain poorly understood. While the master transcription factors OCT4, SOX2, KLF4, and MYC (OSKM) can reprogram normal cells by erasing lineage identity, reprogramming in solid tumors such as PDAC is inefficient, with reprogrammed cells retaining features of their malignant origin, suggesting the presence of active epigenetic barriers. Long noncoding RNAs (lncRNAs) regulate chromatin state and cell identity, but whether they actively enforce cancer-specific transcriptional memory and restrict reprogramming remains largely unexplored. Herein, through CRISPR interference screens targeting cancer-associated lncRNAs, we identified a subset of cancer-associated lncRNAs whose depletion significantly enhanced OSKM-mediated reprogramming in PDAC cells. Knockdown of these lncRNAs enabled the acquisition of pluripotency-associated features, suppressed PDAC identity programs, and reduced tumorigenicity in vivo. Among the most potent repressors of reprogramming were ATXN7L3-AS1, INTS4P2, and AC079921.2, which were upregulated in PDAC but minimally expressed in normal pancreas. ATXN7L3-AS1 and AC079921.2 were associated with mitotic progression and extracellular matrix organization gene programs, respectively, and showed anticorrelation with translational and metabolic gene signatures across TCGA cancer cohorts. These findings uncover a previously unrecognized role for cancer-associated lncRNAs as key enforcers of transcriptional memory in PDAC. By stabilizing malignant identity and opposing reprogramming, these lncRNAs may represent a novel class of epigenetic regulators. Targeting them offers a conceptual and therapeutic framework for erasing cancer cell memory, resetting epigenetic state, and exposing latent vulnerabilities in PDAC.

Similar Papers

biorxiv
Mon Jun 30 2025
Decoding Breast Cancer Heterogeneity via Multi-Omics Integration and Language Model-Based Interpretation
We present a novel pipeline combining Multi-Omics Factor Analysis (MOFA) and fine-tuned Large Language Models (LLMs) to predict breast cancer subtypes using proteomics, DNA methylation, and RNA-Seq data. Breast cancer is a heterogeneous disease characterized by diverse molecular alterations across multiple biological layers, necessitating integrative approaches for accurate subtype classification....
Yasrab, R.
•
Agrawal, R.
•
Saber-Ayad, M.
•
El-Hadidi, M.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Mon Jun 30 2025
Vinorelbine enhances the efficacy of GM-CSF-armed oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma
Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agen...
Drymiotou, S.
•
Queval, C. J.
•
Tyson, K. E.
•
Sheach, L. A.
...•
Way, M.
biorxiv
Mon Jun 30 2025
Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity
Regulatory T cells (Tregs) infiltrate most tumors, yet whether they suppress immune responses directly within tumor tissues is untested. We used intratumoral (IT) delivery of diphtheria toxin (DT) in Foxp3DTR mice to deplete IT Tregs while leaving peripheral Tregs intact. IT delivery of DT reduced Treg frequencies in the tumor, which promoted potent tumor control without autoimmunity. Interestingl...
Bockman, A.
•
Gittins, B.
•
Zhang, C.
•
Hung, J.
...•
DuPage, M.
biorxiv
Mon Jun 30 2025
CD47 blockade enhances immunoradiotherapy response in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promi...
Monther, A.
•
Al-Msari, R.
•
Saddawi-Konefka, R.
•
Fassardi, S.
...•
Califano, J.
biorxiv
Mon Jun 30 2025
NK cell co-localization with epithelial cells in pancreatic cancer is influenced by fibroblasts and ECM components
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive and common type of pancreatic cancer. PDAC has a dense, fibrotic tumor microenvironment (TME) that restricts immune cell infiltration and contributes to poor immunotherapy responses. While T cell-based therapies have been largely ineffective, natural killer (NK) cells-which kill tumor cells without requiring MHC recognition-offer a pro...
Malchiodi, Z. X.
•
Lekan, A. A.
•
Suter, R. K.
•
Deshpande, A.
...•
Weiner, L. M.
biorxiv
Mon Jun 30 2025
Targeting breast cancer senescence in 3D models of bone metastasis
Chemotherapeutic treatment of breast cancer with Doxorubicin can induce tumor and stromal cell senescence leading to therapy-resistance. Senescence-associated secretory phenotype (SASP) promotes secretion of pro-inflammatory and tumorigenic factors causing systemic inflammation. Combined, this can result in immune suppression, tumor growth and secondary spread of cancer. Targeting and removing sen...
Hamburger, E. C. B.
•
Mohseni Garakani, M.
•
Alfaisali, S.
•
Ouellet, J. A.
...•
Rosenzweig, D. H.
biorxiv
Mon Jun 30 2025
Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance
Osimertinib (Osi) resistance remains a significant challenge in EGFR mutant non-small-cell lung cancer (NSCLC). This study investigates the metabolic reprogramming associated with Osi resistance, identifying key metabolic vulnerabilities that may be targeted for therapeutic intervention. Employing the EGFR-mutant H1975 parental (Par) cell line and its Osi-resistant (OsiR) counterpart, we integrate...
Maroni, G.
•
Cabrera San Millan, E.
•
Mercatelli, R.
•
Chiodi, A.
...•
Levantini, E.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Sun Jun 29 2025
Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia
Riboflavin is a diet-derived vitamin in higher organisms that serves as a precursor for flavin mononucleotide and flavin adenine dinucleotide, key cofactors that participate in oxidoreductase reactions. Here, using proteomic, metabolomic and functional genomics approaches, we describe a specific riboflavin dependency in acute myeloid leukemia and demonstrate that, in addition to energy production ...
Bjelosevic, S.
•
Fauth, R.
•
Do, B. T.
•
Alexe, G.
...•
Stegmaier, K.